Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma

被引：0

作者：

Chari, Ajai ^{[1
]}

Dimopoulos, Meletios-Athanasios ^{[2
]}

Beksac, Meral ^{[3
]}

Leleu, Xavier ^{[4
,5
]}

Weisel, Katja ^{[6
]}

Richter, Joshua ^{[7
]}

Dirnberger, Franziska ^{[8
]}

Iskander, Karim ^{[8
]}

Yusuf, Akeem ^{[8
]}

Mikhael, Joseph ^{[9
]}

机构：

[1] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA

[2] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Sch Med, Alexandra Gen Hosp, Athens, Greece

[3] Ankara Univ, Ankara, Turkey

[4] CHU, Serv Hematol & Therapie Cellulaire, Poitiers, France

[5] CIC Inserm 1402, Poitiers, France

[6] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany

[7] Mt Sinai Hosp, Icahn Sch Med, New York, NY 10029 USA

[8] Amgen Inc, Thousand Oaks, CA 91320 USA

[9] City Hope Canc Ctr, Translat Genom Res Inst TGen, Duarte, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-191

引用

页码：S142 / S142

页数：1

共 50 条

[1] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Chari, Ajai
Suvannasankha, Attaya
Fay, Joseph W.
Arnulf, Bertrand
Kaufman, Jonathan L.
Ifthikharuddin, Jainulabdeen J.
Weiss, Brendan M.
Krishnan, Amrita
Lentzsch, Suzanne
Comenzo, Raymond
Wang, Jianping
Nottage, Kerri
Chiu, Christopher
Khokhar, Nushmia Z.
Ahmadi, Tahamtan
Lonial, Sagar
BLOOD, 2017, 130 (08) : 974 - 981
[2] APOLLO: Phase 3 randomized study of subcutaneous Daratumumab plus Pomalidomide and Dexamethasone (D-Pd) versus Pomalidomide and Dexamethasone (Pd) alone in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Einsele, H.
Dimopoulos, M.
Terpos, E.
Boccadoro, M.
Delimpasi, S.
Beksac, M.
Katodritou, E.
Moreau, P.
Baldini, L.
Symeonidis, A.
Bila, J.
Oriol, A.
Mateos, M. -, V
Orfanidis, I
Ahmadi, T.
Ukropec, J.
Kampfenkel, T.
Schecter, J.
Qiu, Y.
Amin, H.
Vermeulen, J.
Carson, R.
Sonneveld, P.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 178 - 178
[3] Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Dimopoulos, Meletios A.
Terpos, Evangelos
Boccadoro, Mario
Delimpasi, Sosana
Beksac, Meral
Katodritou, Eirini
Moreau, Philippe
Baldini, Luca
Symeonidis, Argiris
Bila, Jelena
Oriol, Albert
Mateos, Maria-Victoria
Einsele, Hermann
Orfanidis, Ioannis
Ahmadi, Tahamtan
Ukropec, Jon
Kampfenkel, Tobias
Schecter, Jordan
Qiu, Yanping
Amin, Himal
Vermeulen, Jessica
Carson, Robin
Sonneveld, Pieter
BLOOD, 2020, 136
[4] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
Chari, Ajai
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Blade, Joan
Benboubker, Lotfi
Oriol, Albert
Arnulf, Bertrand
Rodriguez-Otero, Paula
Pineiro, Luis
Jakubowiak, Andrzej
de Boer, Carla
Wang, Jianping
Clemens, Pamela L.
Ukropec, Jon
Schecter, Jordan
Lonial, Sagar
Moreau, Philippe
BLOOD, 2019, 134 (05) : 421 - 431
[5] Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
Spencer, Andrew
Lentzsch, Suzanne
Weisel, Katja
Avet-Loiseau, Herve
Mark, Tomer M.
Spicka, Ivan
Masszi, Tamas
Lauri, Birgitta
Levin, Mark-David
Bosi, Alberto
Hungria, Vania
Cavo, Michele
Lee, Je-Jung
Nooka, Ajay K.
Quach, Hang
Lee, Cindy
Barreto, Wolney
Corradini, Paolo
Min, Chang-Ki
Scott, Emma C.
Chanan-Khan, Asher A.
Horvath, Noemi
Capra, Marcelo
Beksac, Meral
Ovilla, Roberto
Jo, Jae-Cheol
Shin, Ho-Jin
Sonneveld, Pieter
Soong, David
Casneuf, Tineke
Chiu, Christopher
Amin, Himal
Qi, Ming
Thiyagarajah, Piruntha
Sasser, A. Kate
Schecter, Jordan M.
Mateos, Maria-Victoria
HAEMATOLOGICA, 2018, 103 (12) : 2079 - 2087
[6] Updated Results from a Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Isatuximab Plus Pomalidomide and Dexamethasone Versus Daratumumab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
Leleu, Xavier
Delea, Thomas
Guyot, Patricia
Moynahan, Aaron
Singh, Erin
Tekle, Christina
Lin, Peggy L.
BLOOD, 2023, 142
[7] Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
Dimopoulos, Meletios A.
Terpos, Evangelos
Boccadoro, Mario
Delimpasi, Sosana
Beksac, Meral
Katodritou, Eirini
Moreau, Philippe
Baldini, Luca
Symeonidis, Argiris
Bila, Jelena
Oriol, Albert
Mateos, Maria-Victoria
Einsele, Hermann
Orfanidis, Ioannis
Kampfenkel, Tobias
Liu, Weiping
Kosh, Michele
NamPhuong Tran
Carson, Robin
Sonneveld, Pieter
BLOOD, 2022, 140 : 7272 - 7274
[8] Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma
Dima, Danai
Mansour, Razan
Davis, James A.
Minchak, Megan
Goel, Utkarsh
Atallah, Rawan
Logan, Emerson
Tabak, Carine
Rashid, Aliya
Ahmed, Nausheen
Abdallah, Al-Ola
Hashmi, Hamza
EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (06) : 975 - 983
[9] A matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone versus daratumumab plus lenalidomide and dexamethasone for relapsed multiple myeloma
Richter, Joshua
Lin, Peggy
Garcia-Horton, Viviana
Guyot, Patricia
Singh, Erin
Zhou, Zheng-Yi
Sievert, Mark
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S156 - S157
[10] Updated Results from a Matching-Adjusted Indirect Comparison of Efficacy Outcomes of Isatuximab Plus Carfilzomib and Dexamethasone Versus Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
Richter, Joshua
Lin, Peggy L.
Garcia-Horton, Viviana
Guyot, Patricia
Zhou, Zheng-Yi
Sievert, Mark
BLOOD, 2023, 142

← 1 2 3 4 5 →